

## TUESDAY, May 25

### Medical Category Day Agenda

*Room: TBD*

---

- 7:45 am - 8:00 am **Welcome and Introductory Remarks**
- 8:00 am - 9:00 am **Food and Drug Administration (FDA): FDA overview and expectations of clinical investigators**  
CDR Tejashri Purohit-Sheth, MD, USPHS
- This session will provide an overview of the FDA's organizational structure, mission, and review protocols for marketing applications. The presenters also will look at what FDA expects of clinical investigators engaging in clinical research of FDA-regulated products.
- At the end of the session, participants will be able to:
1. Describe FDA's mission.
  2. Describe FDA's procedures for review of marketing applications.
  3. Identify key expectations of clinical investigators conducting clinical trials of FDA-regulated products.
- 9:00 am - 9:30 am **Reducing emergency department visits due to adverse events from medications**  
CDR Daniel Budnitz, MD, MPH, USPHS
- This presentation will review the public health problem and clinical epidemiology of adverse drug events leading to emergency department visits. The presenter will demonstrate the importance of using population-based information to guide and focus safety policies and clinical interventions.
- At the end of the session, participants will be able to:
1. Quantify the public health burden of adverse drug events treated in emergency departments in the US.
  2. Describe 3 types of adverse adverse drug events of public health importance because of frequency, severity or preventability.
  3. Explain how 3 medication safety interventions or policies have been guided by population-based adverse event surveillance.
- 9:30 am - 10:00 am **Single point of access**  
CDR George J Ceremuga, DO, FAAFP, USPHS

This session will examine the Single Point of Access program designed to provide comprehensive quality and continuity of care with expanded clinical hours. The program seeks to meet the needs of patients through increased patient access to care and meet the goals of the Chronic Care Initiative

At the end of the session, participants will be able to:

1. List the goals of the Single Point Of Access program
2. Describe the challenges involved with getting staff and community buy-in
3. Identify the roles and responsibilities of each department

10:00 am - 10:15 am **BREAK**

10:15 am - 11:15 am **Public health service physicians and mental health: 2010 and beyond**

CAPT Marc A. Safran, MD, MPA, USPHS; LCDR Joannette Sorkin, USPHS and CDR Dana Thomas, USPHS

This session will begin with a brief update on mental health challenges currently facing the United States, and on innovations in how mental health is being viewed and addressed. This will be followed by an interactive exploration of challenges facing U.S. Public Health Service physicians of all specialties in addressing mental health needs of their patients. There also will be discussion of challenges U.S. Public Health Service physicians face in maintaining their own resilience. Potential new strategies U.S. Public Health Service physicians might use to meet mental health challenges facing themselves, their patients and the nation in the next decade will be considered.

At the end of the session, participants will be able to:

1. Describe challenges faced by U.S. Public Health Service physicians in addressing mental health needs of their patients.
2. Identify 3 challenges faced by U.S. Public Health Service physicians in maintaining their own resilience.
3. Describe potential strategies U.S. Public Health Service physicians might use to meet the mental health challenges of the next decade.

11:15 am - 11:45 am **Pharmacologic treatment of alcohol dependency**

LCDR Damon Landreau, DO, USPHS

This session will examine the pharmacologic treatment of alcohol addiction. Like other chronic diseases, relapse is a major barrier for successful treatment. Psychosocial rehabilitative programs

remain the back bone of successful treatment. Medications may be a helpful addition to these programs as treatments for relapse. An important aspect of pharmacologic treatment is a basic understanding of the neurobiology of addiction and testing medications that have a known effect in those pathways. In this lecture, a brief review of neurobiology will be tied into a review of how current medications work and why others may be considered for testing.

At the end of the session, participants will be able to:

1. Describe the neurobiology of addiction.
2. List approved medications available for treatment.
3. Identify potential medications for future treatment.

11:45 am - 12:30 pm **BREAK**

12:30 pm - 2:00 pm Luncheon

**Update on key issues facing USPHS Medical Category (45 minutes)**

CAPT Clare Helminiak, MD, MPH, USPHS

This session will provide a comprehensive update on the current issues facing USPHS medical providers.

At the end of the session, participants will be able to:

1. Describe new initiatives for the Medical Category.
2. Describe the status of current ongoing challenges facing public health physicians.
3. Identify 3 issues facing public health physicians in the future.

2:00 pm - 2:30 pm

**Guidelines for prevention and treatment of human papillomavirus in HIV infection**

LCDR Songhai Barclift, MD., USPHS

This session will provide an overview of prevention and treatment issues related to Human Papillomavirus, which is a common, opportunistic infection and the main cause of cervical cancer, anal cancer and some tumors of the vulva, vagina, penis, oral cavity, and oropharynx. Adolescents and adults with HIV are at an increased risk of morbidity and mortality when also infected with an HPV. Understanding the epidemiology, pathophysiology, diagnosis and management of HPV infection is an integral part of caring for individuals with HIV. This session will highlight the important aspects of managing HPV infection. It also will describe and identify the latest tools to prevent HPV exposure and infection.

At the end of the session, participants will be able to:

1. Describe the epidemiology and pathophysiology of Human Papillomavirus (HPV) related diseases (cervical dysplasia, cervical cancer, anal cancer, external warts) in the United States.
2. Identify the clinical manifestations, diagnosis and treatment of Human Papillomavirus related diseases in HIV infected adults and adolescents.
3. Describe the latest efforts to prevent HPV exposure and HPV related disease in HIV infected adults and adolescents. A
4. Prevent HPV exposure and disease in HIV infected individuals.

2:30 pm - 3:00 pm

**HIV+ Long-Term Nonprogressors: Understanding Natural Immune Control of HIV**

CDR Stephen A. Migueles, MD, USPHS

This session will examine how, as the HIV pandemic continues to expand, the need for an effective vaccine has never been greater. Evidence that it is possible for the human immune response to control HIV replication for many years is provided by rare individuals who represent less than 0.5 percent of the infected population. Understanding the mechanisms responsible for this extraordinary phenotype is likely to provide critical information, which could ultimately be applied towards the development of effective HIV/AIDS vaccines and immune-based therapies.

At the end of the session, participants will be able to:

1. Recognize the unique features of HIV+ long-term nonprogressors (LTNP).
2. Describe how studying these rare individuals can contribute to the design of an effective HIV vaccine.
3. Identify the mechanisms believed to underlie durable immune control of HIV.

3:00 pm - 3:15 pm

**BREAK**

3:15 pm - 4:15 pm

**Preventing the functional problems of the two fastest growing segments of our population**

CDR Rochelle Nolte, MD, USPHS

This session will review the epidemiology, basic science, and clinically relevant data on musculoskeletal conditions affecting obese and geriatric patients.

At the end of the session, participants will be able to:

1. Identify risk factors for loss of functional movement.

2. Describe measures that may prevent future disability.
3. List techniques used to manage osteoarthritis.

4:15 pm - 4:45 pm

**H1N1 control at military academies and detention centers**

CDR Joseph Perez, MD, FAAFP, USPHS

This talk will address the recent H1N1 pandemic and its effects on military academies and detention facilities with special emphasis on the Coast Guard Academy

At the end of the session, participants will be able to:

1. Describe the case definitions of influenza-like illness and H1N1 influenza.
2. Describe the infectivity of H1N1 and its transmissibility from human to human.
3. Identify the special challenges posed to control of outbreaks in institutionalized settings.
4. Describe outbreak control carried out by the Coast Guard Academy to control an outbreak.

4:45 pm - 5:15 pm

**Closing Remarks**